Appetite suppression is the dominant, well-evidenced mechanism behind GLP-1 and dual GIP/GLP-1 drugs. It is probably most of the story — but a patient losing a stone in six weeks on a sub-licensed dose, with almost no dietary change, sits in the part it does not comfortably explain. The grown-up response to that gap is not to pretend, but to ask better questions. This series asks one of them.
.png)
